Biopharma

Selected news for the healthcare topic - Biopharma, collected since 6/2019. Recent stories appear in Ticker Report and Daily Political. This healthcare topic shares news with Oncology, COVID-19, Biotech, Pfizer, Novartis and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/13/2021 Director, Clinical Development Physician - Kite from zobjobs.com zobjobs.com ... site to ensure the health and safety of our teams. For Current Kite Pharma Employees and Contractors: Please log onto your Internal Career Site to apply for this job. Job Description Kite is a biopharma ceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR ...
6/13/2021 Mesoblast (OTCMKTS:MEOBF) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00 theenterpriseleader.com ... as high as $1.63. Mesoblast shares last traded at $1.63, with a volume of 2,000 shares traded.The business’s 50 day moving average is $1.54.Mesoblast Company Profile ( OTCMKTS:MEOBF )Mesoblast Limited, a biopharma ceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based ...
6/10/2021 The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga ... S (NYSE: NVO ) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) Sesen Bio, Inc. (NASDAQ: SESN ) Down In The Dumps None of the NYSE or Nasdaq-listed biopharma /medical devices/molecular diagnostics stock hit 52-week lows Wednesday.Stocks In Focus 500M Doses Of Pfizer, BioNTech Vaccine Destined For Countries In Need Pfizer Inc. (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) announced plans ...
6/10/2021 AI-drug discovery biotech Valo Health is going public via a $2.8B SPAC merger - MedCity News MedCity News Artificial Intelligence , BioPharma AI-drug discovery biotech Valo Health is going public via a $2.8B SPAC merger Valo Health is going public in a SPAC merger. Less than nine months removed from its formal launch, Valo is now revealing more about its artificial intelligence platform technology, which it plans to use to make the firm the first “digitally native” pharmaceutical company ...
6/10/2021 Day 2 of INVEST Precision Medicine: Life science startup pitches, biopharma software R&D, and more - MedCity News MedCity News MedCity INVEST Precision Medicine brings together regional and national stakeholders across healthcare, biopharma, and medtech to discuss new developments in precision medicine, the reality on the ground, and what needs to happen for more widespread adoption and integration of these innovative technologies.Click here to register now!Here’s what’s happening on Day 2 of the online conference:Software Supporting Biopharma R&D 10:30-11:30 am ET(Sponsored by Komodo ...
6/9/2021 Does Eli Lilly Have the Next B - GuruFocus.com gurufocus.com ... approval set a precedent in that it indicated the regulatory agency would accept a lowering of amyloid as predictive of effectiveness, thus opening the window for other drugs that focus on this measure, reported Biopharma Dive.Among those candidates is donanemab. Eli Lilly recently released encouraging phase 2 trial results for the drug. In testing, it cut brain plaque levels and slowed the decline in patients by 32% versus placebo ...
6/9/2021 Antisense & RNAi Therapeutics Global Market Report 2021: COVID 19 Growth And Change to 2030 Globe Newswire Antisense & RNAi Therapeutics Global Market Report 2021: COVID 19 Growth And Change to 2030 Major players in the Antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd. , Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S. June 09, 2021 05:23 ET ReportLinker Lyon, FRANCENew York, June 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antisense & RNAi Therapeutics Global Market Report 2021: COVID ...
6/9/2021 Cell Therapy Technologies Industry Trends Involve Partnerships, Acquisitions Among Major Players einnews.com ... intelligence (AI)-driven cell analysis and sorting system.In March 2020, Danaher Corporation, a USA-based company that designs, manufactures, and markets professional, medical, industrial, and commercial products, and services acquired General Electric (GE) biopharma business for $21.4 billion. The biopharma business was a part of the GE life sciences division that offered software and equipment used in biopharma ceutical research. The acquisition is expected to expand Danaher’s life sciences ...
6/9/2021 Biden admin to purchase 500 million Pfizer COVID-19 vaccine doses to distribute to needy countries FiercePharma ... waiver talks move forward at the World Trade Organization. Under a proposal backed by the U.S. government, vaccine manufacturers around the world could sidestep COVID-19 vaccine patents to produce their own shots. The biopharma industry strongly opposes the proposal.RELATED: AstraZeneca in talks to produce COVID-19 vaccine for feds at Catalent site in Maryland: reportIt's not just Pfizer vaccine doses the U.S. government is donating. In April ...
6/9/2021 CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16 Yahoo News SEATTLE , June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET . The conference will be held in a virtual meeting format.CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.) Presentation details:Event: JMP Securities Life Sciences ConferenceDate: Wednesday, June 16, 2021Time: 2:30 p.m. ETThe presentation will be webcast ...
6/8/2021 Foundation Medicine Launches FoundationOneTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera | Financial Buzz financialbuzz.com ... a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies.“The addition of FoundationOne Tracker for research use provides our biopharma and academic partners access to Foundation Medicine’s broad, advanced-stage CGP footprint,” said Foundation Medicine’s Chief Scientific Officer Priti Hegde. “In partnering with Natera, we have been able to leverage the best ...
6/4/2021 Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology ...-annual-congress.html) biomedreports.com ... from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ETBOSTON, June 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharma ceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it will present Phase 2a clinical trial and Phase 2a open label extension ...
6/4/2021 Folger Nolan Fleming Douglas Capital Management Inc. Sells 461 Shares of Bristol-Myers Squibb (NYSE:BMY) Dakota Financial News ... StocktwitsFolger Nolan Fleming Douglas Capital Management Inc. lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.1% in the 1st quarter, HoldingsChannel reports. The fund owned 14,303 shares of the biopharma ceutical company’s stock after selling 461 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $903,000 as of its most recent SEC filing.A number ...
6/4/2021 Atria Investments LLC Acquires 7,380 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) baseballnewssource.com ... in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,149 shares of the biopharma ceutical company’s stock after purchasing an additional 7,380 shares during the period. Atria Investments LLC’s holdings in Gilead Sciences were worth $4,534,000 at the end of the most recent reporting period.Other large investors ...
6/4/2021 Bristol-Myers Squibb (NYSE:BMY) Position Lessened by Banque Pictet & Cie SA - American Banking News American Banking News Share on StocktwitsBanque Pictet & Cie SA reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 62.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,358 shares of the biopharma ceutical company’s stock after selling 80,895 shares during the period. Banque Pictet & Cie SA’s holdings in Bristol-Myers Squibb were worth $3,116,000 at ...
6/4/2021 Folger Nolan Fleming Douglas Capital Management Inc. Has $903,000 Position in Bristol-Myers Squibb (NYSE:BMY) The Markets Daily ... Myers Squibb (NYSE:BMY) by 3.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,303 shares of the biopharma ceutical company’s stock after selling 461 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $903,000 as of its most recent SEC filing.Several other ...
6/4/2021 Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Fosun International Ltd The Markets Daily ... Ltd increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 112,798 shares of the biopharma ceutical company’s stock after acquiring an additional 13,395 shares during the quarter. Gilead Sciences makes up 0.6% of Fosun International Ltd’s holdings, making the stock its 22nd largest holding. Fosun International Ltd’s holdings ...
6/4/2021 Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting digitalmedianet.com ... Posted on June 4, 2021 Neratinib efficacy evidenced in patients with EGFR exon 18-mutant non-small cell lung cancer and CNS involvementLOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharma ceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC), including patients with central nervous system ...
6/4/2021 Atria Investments LLC Has $4.53 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) com-unik.info ... 4th, 2021 Share on StocktwitsAtria Investments LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 70,149 shares of the biopharma ceutical company’s stock after acquiring an additional 7,380 shares during the quarter. Atria Investments LLC’s holdings in Gilead Sciences were worth $4,534,000 as of its most recent SEC filing.Other hedge funds have also ...
6/4/2021 Signet Investment Advisory Group Inc. Raises Stock Holdings in Eaton Co. plc (NYSE:ETN) | Daily Political Daily Political AMG National Trust Bank trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.7% in the first quarter, HoldingsChannel reports. The firm owned 12,900 shares of the biopharma ceutical company’s stock after selling 1,083 shares during the period. AMG National Trust Bank’s holdings in Gilead Sciences were worth $834,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also ...